Glykrez 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glykrez 80 is typically prescribed when diet, exercise, and weight reduction alone have not achieved adequate blood glucose regulation. The medication is absorbed rapidly from the gastrointestinal tract, with a duration of action suitable for once or twice daily dosing, depending on clinical response. It is essential to monitor blood glucose levels regularly to adjust the dosage and minimize the risk of hypoglycemia, a common adverse effect associated with sulfonylureas. Glykrez 80 should be used cautiously in patients with hepatic or renal impairment and is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Patient education on recognizing symptoms of hypoglycemia and adherence to prescribed lifestyle modifications enhances therapeutic outcomes. This medication should be used under medical supervision, with periodic assessment of glycemic control and potential side effects to ensure optimal diabetes management.